0
Obstructive Lung Diseases |

Comparison of the Preference, Satisfaction, and Critical Errors Made With Genuair® and HandiHaler® in patients with COPD

Job van der Palen, MD; Thomas Ginko, MD; Axel Kroker, MD; Paul van der Valk, MD; Martijn Goosens, MD; Laura Padulles; Beatriz Seoane, MMSc; Ludmyla Rekeda, PhD; Esther Garcia Gil*, MD
Author and Funding Information

University of Twente, Enschede, Netherlands


Chest. 2012;142(4_MeetingAbstracts):717A. doi:10.1378/chest.1381326
Text Size: A A A
Published online

Abstract

SESSION TYPE: COPD Posters I

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: In COPD, patient preference and satisfaction with their inhaler and proper inhaler technique may influence treatment outcomes. Patients often use their inhaler incorrectly, making critical errors that may result in receiving no drug or a suboptimal dose, leading to under-treatment of their disease. This study investigated patient preference, satisfaction and critical errors with Pressair/Genuair® versus HandiHaler® after 2 weeks of daily use.

METHODS: This was an open-label, randomised, crossover, multicentre study in patients with COPD. Patients inhaled placebo through Pressair/Genuair® and HandiHaler® daily for 2 weeks in addition to their current medication. Primary endpoint was the percentage of patients who preferred Pressair/Genuair® after 2 weeks. Additional endpoints for each inhaler were overall patient satisfaction on a scale of 1 (very dissatisfied) to 5 (very satisfied), percentage of patients making ≥1 critical errors and willingness to continue using each inhaler rated from 0 (not) to 100 (definitely). Data were analysed using Mainland-Gart’s test or ANOVA.

RESULTS: The ITT population included 105 patients. Significantly more patients indicated a preference for Pressair/Genuair® versus HandiHaler® (79.1% versus 20.9%, respectively; p<0.0001) at study end. Patient satisfaction was significantly higher with Pressair/Genuair® after 2 weeks (least squares mean: 4.6 versus 3.8 for HandiHaler®; p<0.0001), as was the percentage of patients ‘very satisfied’ with the inhaler (54.8% versus 19.0%, respectively; p<0.0001). After 2 weeks, 10.5% of patients using Pressair/Genuair® and 26.7% of patients using HandiHaler® made ≥1 critical error (p<0.0001) and significantly more patients indicated a willingness to continue using Pressair/Genuair® versus HandiHaler® (least squares mean: 84.0 versus 62.5, respectively; p<0.0001).

CONCLUSIONS: More patients using Pressair/Genuair® were ‘very satisfied’, made fewer critical errors and preferred Pressair/Genuair® compared with HandiHaler®.

CLINICAL IMPLICATIONS: Pressair™/Genuair® was associated with higher patient preference, satisfaction and fewer critical inhaler errors than HandiHaler®, which are important considerations for physicians and patients as they can influence adherence and the effectiveness of treatment. This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc., New York, USA

DISCLOSURE: Job van der Palen: Other: Research sponsored by Almirall

Laura Padulles: Employee: Almirall SA

Beatriz Seoane: Employee: Almirall SA

Ludmyla Rekeda: Employee: Forest Research Institute

Esther Garcia Gil: Employee: Almirall SA

The following authors have nothing to disclose: Thomas Ginko, Axel Kroker, Paul van der Valk, Martijn Goosens

No Product/Research Disclosure Information

University of Twente, Enschede, Netherlands

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543